Lung cancer risk (17 studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes lung cancer risk No. of participants: 371,067 (11 observational… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Breast cancer risk (14 studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes breast cancer risk (women) No. of participants: 169,028 (8… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Bladder cancer risk No. of participants: 279,100 (5 observational studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes bladder cancer risk No. of participants: 279,100 (5 observational… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Prostate cancer risk (13 studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes prostate cancer risk No. of participants: 576,667 (21 observational… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Any cancer risk No. of participants: 76,239 (7 observational studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes any cancer risk No. of participants: 76,239 (7 observational studies) compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
All-cause mortality (ACM) · Adults (any age) with a known number of remaining teeth, followed prospectively in cohort studies
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for all-cause mortality (11 studies, I2=89%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
3 findings from 1 review
Atherosclerotic cardiovascular disease (ACVD)-related events (morbidity and mortality) · Adults (any age) with a known number of remaining teeth, followed prospectively in cohort studies
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for ACVD-related events (13 studies, I2=75%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
3 findings from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (at end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review